OU Internal Medicine Residency

OU Internal Medicine Residency
Oklahoma City, OK

[Anh Lam (she/her) @anhbl9]

Thank you so much for highlighting our work, @crisbergerot!

I am so excited to present about longitudinal coping among early phase cancer clinical trial participants at #ASCO26, and I am especially honored to have been awarded a @ConquerCancerFd for Merit Award for this work🥹

[Anh Lam (she/her) @anhbl9]

I am very honored to present this rapid oral abstract on behalf of Dr @LundquistDebra and our amazing team at #ASCO26!

I’m so deeply appreciative of Dr Lundquist and Dr @RyanNipp for your mentorship and our phenomenal team who took me in and supported me these past few years💛

[Anh Lam (she/her) @anhbl9]

Lastly, thank you to the residents of our great program who elected us to be your Chiefs and trusted us to lead you & support you. This has been an incredibly transformative year, and it has been an honor for us to advocate for and work with you all this year🥹

[Anh Lam (she/her) @anhbl9]

My co-chiefs and I presented at @OUdoim Grand Rounds this afternoon and shared many of our initiatives throughout our CMR year with @OU_internalmed!

What an honor it has been to serve our program and establish foundations to pave way for future residents🫶

[Anh Lam (she/her) @anhbl9]

Thank you so so much to the amazing faculty & fellows we collaborated with this year, who work tirelessly to support our residents from the sim lab, to the research curriculum, fellowship bootcamp, and much much more. We couldn’t have been successful this year without you all.

[Yusra Minahil Nasir @YusraMinahil]

Grateful to have our work published in Reviews in Cardiovascular Medicine.

Thankful to Dr. Mattumpuram for his mentorship and to all collaborators for their valuable contributions to this project.

Read full article: https://t.co/WfyexDqmoN

[OU Internal Medicine Residency @OU_internalmed]

3️⃣ Recurrent DVT rates were similar (~1%), highlighting bleeding risk as a key driver in anticoagulant selection

#JournalClub #MedTwitter #Hematology #VTE #OUHealth

[OU Internal Medicine Residency @OU_internalmed]

📚 Journal Club Recap

Two weeks ago, we discussed:

“Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism”
Published in the New England Journal of Medicine
🔗 https://t.co/j6cbOW8Yss

[OU Internal Medicine Residency @OU_internalmed]

Key Takeaways:
1️⃣ Apixaban significantly reduces bleeding vs. rivaroxaban (RR 0.46; ARR 3.8%)
2️⃣ Pragmatic randomized trial design effectively addresses clinical equipoise in real-world settings

[OU Internal Medicine Residency @OU_internalmed]

3️⃣ Oral small-molecule GLP-1s are an effective alternative to injectables for weight loss in Type II diabetes

#JournalClub #GLP1 #DiabetesResearch #MedTwitter

[OU Internal Medicine Residency @OU_internalmed]

📚 Journal Club Recap

Two weeks ago, we discussed a recent article from The Lancet:

“Orforglipron, a nonpeptide oral GLP-1 receptor agonist, in adults with type 2 diabetes”

🔗 https://t.co/eiimE8SFpn

[OU Internal Medicine Residency @OU_internalmed]

Key Takeaways:
1️⃣ Parallel-arm, multi-dose designs enable simultaneous efficacy assessment without dose-dependent bias
2️⃣ Oral GLP-1s (e.g., Orforglipron) show strong cardiometabolic improvements consistent with injectable agents

[OU Department of Internal Medicine @OUdoim]

(2/2)

[OU Department of Internal Medicine @OUdoim]

Congratulations to our exceptional interns! We’re thrilled to announce and celebrate this wonderful Match for our Internal Medicine Program here at OU. We couldn’t be more excited for this amazing group to join us!

Happy Match Day, everyone! #matchday2026

(1/2)

[OU Internal Medicine Residency @OU_internalmed]

📊 Key takeaways:

• Evolocumab ↓ first MACE vs placebo in high-risk ASCVD or diabetes patients without prior MI/stroke
• ~55% ↓ LDL-C on top of statins, supporting primary prevention benefit
• Future focus: cost-effectiveness & clinical integration

[OU Internal Medicine Residency @OU_internalmed]

📌 Journal Club – Feb 16, 2026

Topic: What is the effect of evolocumab as primary prevention for patients with ASCVD or diabetes without prior MI or stroke?

#ASCVD #DiabetesCare #PrimaryPrevention #Evolocumab #LipidManagement #PreventiveCardiology #ClinicalResearch

[OU Internal Medicine Residency @OU_internalmed]

PICO:

👥 P: ASCVD or diabetes, no prior MI/stroke
💊 I: Evolocumab + standard lipid therapy
⚖️ C: Placebo + standard therapy
📉 O: ↓ LDL-C & ↓ first MACE